Ligandrol (LGD-4033, later VK5211) is an oral selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals. It is an investigational drug and is not FDA approved.
Also known as: LGD-4033, VK5211.
There is no approved product. The phase 1 trial in healthy young men used 0.1, 0.3 or 1 mg once daily for 21 days (Basaria 2013).
Ligandrol is not FDA approved; it is an investigational drug. FDA says SARMs are unapproved drugs that cannot be legally marketed in the US as dietary supplements or drugs, and lists risks including liver injury and acute liver failure, a higher risk of heart attack or stroke, and effects on fertility. FDA warning letters name LGD-4033 among unapproved new drugs and say it is excluded from the dietary supplement definition.
In the phase 1 trial (Basaria 2013), HDL cholesterol fell at doses of 0.3 mg and above (by about 19 mg/dL at 1 mg) and returned to baseline after stopping. Total testosterone and SHBG fell with dose, and FSH and free testosterone fell at 1 mg. Liver enzymes, PSA, hemoglobin and QT did not change significantly in that 3-week study. These are trial protocols, not personalized advice; confirm any dosing with your prescriber.
In the phase 1 trial in healthy young men (Basaria 2013), LGD-4033 had a long elimination half-life of 24 to 36 hours, and blood levels on day 21 were nearly three times those on day 1. Dose Track uses 30 hours. The paper gives no single time to peak, so we do not list one.
Numbers shown are the values Dose Track uses, listed only where they agree with the source above. Half-life varies from person to person and with injection site.